Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
Yasmin AlfalloujiAshley SpencerEduardo CalonjeConal M PerrettRichard Edward WatchornCatherine BorysiewiczTara HodgkinsonHarpreet WasanChristopher Barry BunkerRachel U SidwellPublished in: Clinical and experimental dermatology (2022)
Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer. BRAF inhibitors have been reported to be associated with new and changing melanocytic lesions, including eruptive naevi. We describe two cases of eruptive naevi secondary to encorafenib used for the treatment of BRAF-mutant metastatic colorectal cancer.